99bet win login StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH)MELBOURNE, Australia (AP) — Australia's House of Representatives passes bill banning children younger than age 16 from social media.Liverpool player ratings as Cody Gakpo brilliant and two others superb vs Leicester City

Manmohan Singh, India's reluctant prime minister, diesNordson Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

Bieber re-signs with GuardiansAfter his team's 102-89 home win on Wednesday night over Purdue Fort Wayne, Penn State coach Mike Rhoades challenged his team's fan base to show up and make more noise. "Sweat with us," he said at one point. At 5-0, the Nittany Lions haven't had to sweat much to get off to a fast start. They might not have to expend much perspiration to make it 6-0 on Monday when they meet Fordham in a semifinal matchup at the Sunshine Slam tournament in Daytona Beach, Fla. Penn State hasn't played a strong schedule so far, but the team has been impressive. It's averaging 98.2 points per game and 13.8 steals per game, both of which ranked second in Division I through Saturday's play. The Nittany Lions were seventh per kenpom.com in turnover rate, forcing 25.3 per 100 possessions. Point guard Ace Baldwin Jr. is leading the charge, scoring 16.4 points and dishing out 7.8 assists while chipping in 2.6 steals. Zach Hicks has nearly doubled his scoring average from 8.4 last season to 15.8 this season, while Northern Illinois transfer Yanic Konan Niederhauser has beefed up the interior, tallying 12.2 points and 7.2 rebounds. Meanwhile, Fordham (3-3) is coming off a 73-71 home loss Friday night against Drexel in New York. The Rams blew a seven-point lead early in the second half and missed a chance to force overtime when leading scorer Jackie Johnson III missed a layup as time expired. Johnson, a UNLV transfer, is averaging 19 points per game and is making nearly 48 percent of his shots as one of three Rams with double-figure scoring averages. Jahmere Tripp scores at an 11.0 clip while Japhet Medor is contributed 10.5, but Fordham is struggling to make shots, canning only 41.5 percent from the field. The Rams were picked for a 14th-place finish in the Atlantic 10 despite returning more scoring than any team in the league except for VCU. Third-year coach Keith Urgo thinks his team can defy low external expectations. "We're experienced and I think we're poised to have a tremendous year," he said. --Field Level Media

Empowered Funds LLC raised its stake in ManpowerGroup Inc. ( NYSE:MAN – Free Report ) by 51.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 11,190 shares of the business services provider’s stock after purchasing an additional 3,789 shares during the quarter. Empowered Funds LLC’s holdings in ManpowerGroup were worth $823,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in MAN. Tidal Investments LLC lifted its holdings in shares of ManpowerGroup by 179.7% during the 1st quarter. Tidal Investments LLC now owns 17,327 shares of the business services provider’s stock valued at $1,345,000 after buying an additional 11,132 shares during the last quarter. CWM LLC lifted its stake in ManpowerGroup by 5,109.1% in the second quarter. CWM LLC now owns 7,449 shares of the business services provider’s stock valued at $520,000 after acquiring an additional 7,306 shares during the last quarter. Quadrature Capital Ltd grew its position in ManpowerGroup by 140.0% in the first quarter. Quadrature Capital Ltd now owns 20,437 shares of the business services provider’s stock worth $1,587,000 after acquiring an additional 11,921 shares in the last quarter. Burney Co. increased its stake in shares of ManpowerGroup by 2.0% during the 1st quarter. Burney Co. now owns 17,607 shares of the business services provider’s stock worth $1,367,000 after purchasing an additional 353 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of ManpowerGroup during the 2nd quarter valued at $667,000. Hedge funds and other institutional investors own 98.03% of the company’s stock. ManpowerGroup Stock Up 2.8 % ManpowerGroup stock opened at $62.48 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.15 and a quick ratio of 1.15. ManpowerGroup Inc. has a fifty-two week low of $59.35 and a fifty-two week high of $80.25. The firm has a fifty day moving average price of $67.49 and a two-hundred day moving average price of $70.65. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of 79.09 and a beta of 1.46. ManpowerGroup Increases Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Monday, December 2nd will be given a $1.545 dividend. This represents a $6.18 annualized dividend and a dividend yield of 9.89%. This is a boost from ManpowerGroup’s previous quarterly dividend of $1.01. The ex-dividend date is Monday, December 2nd. ManpowerGroup’s dividend payout ratio is currently 389.88%. Wall Street Analyst Weigh In A number of equities research analysts recently issued reports on the stock. Truist Financial decreased their price objective on shares of ManpowerGroup from $78.00 to $74.00 and set a “hold” rating for the company in a report on Friday, October 18th. UBS Group lowered their price objective on ManpowerGroup from $78.00 to $71.00 and set a “neutral” rating on the stock in a report on Friday, October 18th. Finally, BMO Capital Markets cut their price objective on ManpowerGroup from $87.00 to $71.00 and set a “market perform” rating on the stock in a research note on Friday, October 18th. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, ManpowerGroup currently has an average rating of “Hold” and a consensus target price of $76.60. Get Our Latest Report on ManpowerGroup Insider Buying and Selling In other news, CFO John T. Mcginnis bought 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 23rd. The shares were acquired at an average cost of $62.28 per share, with a total value of $498,240.00. Following the completion of the transaction, the chief financial officer now directly owns 70,639 shares in the company, valued at $4,399,396.92. This represents a 12.77 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink . 2.40% of the stock is currently owned by insiders. ManpowerGroup Profile ( Free Report ) ManpowerGroup Inc provides workforce solutions and services worldwide. The company offers recruitment services, including permanent, temporary, and contract recruitment of professionals, as well as administrative and industrial positions under the Manpower and Experis brands. It also offers various assessment services; training and development services; career and talent management; and outsourcing services related to human resources functions primarily in the areas of large-scale recruiting and workforce-intensive initiatives. Featured Stories Want to see what other hedge funds are holding MAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ManpowerGroup Inc. ( NYSE:MAN – Free Report ). Receive News & Ratings for ManpowerGroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ManpowerGroup and related companies with MarketBeat.com's FREE daily email newsletter .The Dallas Cowboys (3-7) visit the Washington Commanders (7-4) on Sunday, November 24, 2024 at Commanders Field and will aim to break a five-game losing streak. What channel is Commanders vs. Cowboys on? What time is Commanders vs. Cowboys? The Commanders and the Cowboys play at 1 p.m. ET. NFL STATS CENTRAL: The latest NFL scores, schedules, odds, stats and more. Commanders vs. Cowboys betting odds, lines, spread Commanders vs. Cowboys recent matchups Commanders schedule Cowboys schedule NFL week 12 schedule This content was created for Gannett using technology provided by Data Skrive.

Mutual of America Capital Management LLC cut its position in Blueprint Medicines Co. ( NASDAQ:BPMC – Free Report ) by 0.9% in the third quarter, HoldingsChannel.com reports. The firm owned 32,144 shares of the biotechnology company’s stock after selling 302 shares during the period. Mutual of America Capital Management LLC’s holdings in Blueprint Medicines were worth $2,973,000 as of its most recent SEC filing. Other hedge funds have also modified their holdings of the company. Hsbc Holdings PLC bought a new position in shares of Blueprint Medicines during the 2nd quarter worth approximately $1,060,000. Comerica Bank lifted its holdings in shares of Blueprint Medicines by 2,582.9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock valued at $1,028,000 after purchasing an additional 10,435 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Blueprint Medicines by 27.8% in the 2nd quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company’s stock worth $6,721,000 after purchasing an additional 13,579 shares in the last quarter. SG Americas Securities LLC grew its stake in Blueprint Medicines by 82.8% during the 2nd quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company’s stock worth $2,337,000 after buying an additional 9,819 shares during the last quarter. Finally, Nicholas Investment Partners LP acquired a new position in Blueprint Medicines during the 2nd quarter valued at about $4,377,000. Blueprint Medicines Price Performance Shares of NASDAQ BPMC opened at $94.15 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27. The firm’s 50 day simple moving average is $90.36 and its 200-day simple moving average is $98.53. Blueprint Medicines Co. has a 12 month low of $66.61 and a 12 month high of $121.90. The stock has a market capitalization of $5.98 billion, a price-to-earnings ratio of -44.62 and a beta of 0.59. Analysts Set New Price Targets Several equities research analysts have weighed in on the company. Barclays raised their price target on Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a report on Monday, July 29th. Wedbush reissued an “outperform” rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Thursday, November 14th. JPMorgan Chase & Co. initiated coverage on shares of Blueprint Medicines in a report on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price target for the company. Baird R W upgraded shares of Blueprint Medicines to a “strong-buy” rating in a research note on Friday, August 2nd. Finally, Guggenheim upped their target price on Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.11. View Our Latest Research Report on BPMC Insider Activity In other news, insider Fouad Namouni sold 3,633 shares of the stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the transaction, the insider now owns 69,070 shares in the company, valued at $6,169,332.40. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website . Insiders own 4.21% of the company’s stock. About Blueprint Medicines ( Free Report ) Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. Further Reading Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. ( NASDAQ:BPMC – Free Report ). Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter .A shareholder has sued Warner Bros. Discovery , the soon-to-be former home of the NBA , for violating securities law by misleading investors on the impact of losing its long-standing rights deal with the league. Richard Collura filed the suit in New York federal court seeking class action status on behalf of shareholders who purchased WBD stock between February 23 and August 7 of 2024, which is when the media giant took a massive $9.1 billion write-down at its networks segment related in part, it said, to losing the NBA on TNT. With linear television in decline, Paramount also took a large write-down in the same quarter. Under its existing 2014 deal with the NBA, TNT paid an annual average fee of $1.2 billion. 4. In 2024, the NBA entered advanced discussions with its various partners for a new round of media-rights deals that would last approximately a decade. WBD was unable to reach a new deal with the NBA before its exclusive negotiating window expired in April 2024, allowing the NBA to negotiate with other companies for its sports rights content, including, inter alia, NBC, which offered to pay an annual average fee of $2.5 billion, and Amazon, which offered to pay an annual average fee of $1.8 billion. The suit claims defendants, which also include WBD’s CEO David Zaslav and CFO Gunnar Wiedenfels , “made materially false and misleading statements regarding the company’s business, operations, and prospects,” during the period specified and “failed to disclose that WBD’s sports rights negotiations with the NBA were causing, or were likely to cause, the company to significantly reevaluate its business and goodwill.” Basically, it says the WBD defendants routinely “overstated WBD’s overall business and financial prospects” – like Zaslav stating on the first quarter call that WBD was “now on solid footing with a clear pathway to growth” and that the company is confident in its “ability to drive sustained operating momentum and enhanced shareholder value.” WBD’s stock price fell by 69 cents, or about 9.to close at $7.02 per share. It’s gained back ground since, closing Tuesday at $10.11. Bigger picture the shares have fallen precipitously since Discovery acquired Warner Media. “As a result of Defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the Company’s securities, Plaintiff and other Class members have suffered significant losses and damages.” There were warnings about the business and sports rights in the company’s 10k and other filings, but the suit dismisses them as “generic” boilerplate that didn’t acknowledge the actual risk. WBD had also sued the NBA for awarding its package to Amazon and in that lawsuit said the loss of the rights deal would be devastating. (The NBA and WBD subsequently reached a settlement that includes putting NBA games on Max in some international markets and a related deal with ESPN, which also has a package, to keep Inside the NBA on air.) “During the Class Period, Defendants engaged in a plan, scheme, conspiracy and course of conduct, pursuant to which they knowingly or recklessly engaged in acts, transactions, practices and courses of business which operated as a fraud and deceit upon Plaintiff and the other members of the Class; made various untrue statements of material facts and omitted to state material facts ... [to] artificially inflate and maintain the market price of WBD securities,” the said claimed, seeking damages.

Maharashtra Deputy Chief Minister Ajit Pawar pays tribute to Manmohan Singh